Neurodegeneration: Fly model sheds light on brain disease
Neuronal ceroid lipofuscinosis (NCL) refers to a group of progressive brain diseases that affect between 1 and 30 per 100,000 people and are characterized by a decline in motor abilities, seizures, dementia and premature death (Nosková et al., 2011; Haltia, 2003). Most NCLs are caused by the failure of cells to recycle various proteins inside lysosomes (Wisniewski et al., 2001; Henderson et al., 2016; Sambri et al., 2017; Warrier et al., 2013). However, one type of neuronal ceroid lipofuscinosis is different: CLN4 disease occurs when a patient inherits one mutant copy of the gene that encodes for a protein called CSPɑ, but the precise cellular dysfunction underlying CLN4 disease remains a mystery (Nosková et al., 2011; Benitez and Sands, 2017).
Mutations in this gene have been associated with both loss and gain of function. In theory, the mutations could deplete normal CSPɑ, and this loss of function could contribute to disease pathology. Alternatively, the mutations could enhance the normal activity of CSPɑ or lead to an additional, toxic function to drive disease pathology. Now, in eLife, Konrad Zinsmaier and colleagues at the University of Arizona and Yale University – including Elliot Imler as first author – report the generation of a new animal model to investigate the biological mechanisms underlying CLN4 disease (Imler et al., 2019).
Imler et al. started by expressing either the normal or mutant human forms of CSPɑ in flies and confirming that both were functional in fly cells. Next they confirmed that mutant forms of CSPɑ could mimic pathological features seen in CLN4 patients. Interestingly, they found that the severity of the disease correlated with the copy number of the mutated gene: a single copy of the mutated gene did not affect lifespan, but two copies led to more severe phenotypes and early death. To confirm that these results were not an artifact of expressing a human protein in flies, Imler et al. repeated many of their experiments using mutant versions of fly CSPɑ.
The Arizona–Yale team then looked at where mutant CSPɑ resides in neurons. Normally, one would expect to find CSPɑ at nerve terminals, but the mutations resulted in lower levels of the protein at nerve terminals and higher levels in regions of the cell that contained other proteins that had been marked for degradation. By using markers of different cellular components, the researchers demonstrated that mutant CSPɑ was accumulating on prelysosomal endosomes. An endosome is a mini-compartment within a cell that internalizes molecules from the cell membrane: the endosome then fuses with an organelle called a lysosome, and the molecules inside it are broken down and recycled. Imler et al. hypothesize that mutant CSPɑ may be re-routed from nerve terminals through the endolysosomal pathway. Consistent with this, electron microscopy revealed the formation of abnormal membrane structures in cells, which may be due to mutant CSPɑ congesting the trafficking system.
Next, Imler et al. modulated the levels of normal and mutant CSPɑ in cells. Reducing the level of normal CSPɑ reduced the mutant phenotypes, while increasing it exacerbated the mutant phenotypes. Similarly, reducing the level of a heat shock protein that normally interacts with CSPɑ attenuated mutant phenotypes, suggesting that the heat shock protein may play a role in disease biology. The Arizona–Yale team suggests that the disease-causing mutations in CSPɑ enhance its normal activity to disrupt the function of neurons. This gain-of-function mechanism is distinct from that found in the other NCLs, which typically arise from a deficiency in the function of the mutated gene.
The results of Imler et al. demonstrate the value of the fruit fly model to study CLN4 disease pathology. However, these results also paint a complex picture of CLN4, and much work remains to be done to understand how each molecular or cellular pathology contributes to the devastating cognitive and motor deficits found in patients. Future work can now focus on how these biochemical disruptions impact neuronal function over time, taking advantage of the many tools and techniques available in fly genetics in order to interrogate pathways that have additive or compensatory mechanisms that may someday yield therapeutic potential.
References
-
The neuronal ceroid-lipofuscinosesJournal of Neuropathology & Experimental Neurology 62:1–13.https://doi.org/10.1093/jnen/62.1.1
-
Mutations in DNAJC5, encoding cysteine-string protein alpha, cause autosomal-dominant adult-onset neuronal ceroid lipofuscinosisAmerican Journal of Human Genetics 89:241–252.https://doi.org/10.1016/j.ajhg.2011.07.003
-
Genetic basis and phenotypic correlations of the neuronal ceroid lipofusinosesBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1832:1827–1830.https://doi.org/10.1016/j.bbadis.2013.03.017
Article and author information
Author details
Publication history
Copyright
© 2019, Berryer et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 766
- views
-
- 71
- downloads
-
- 0
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Neuroscience
The concept that dimeric protein complexes in synapses can sequentially replace their subunits has been a cornerstone of Francis Crick’s 1984 hypothesis, explaining how long-term memories could be maintained in the face of short protein lifetimes. However, it is unknown whether the subunits of protein complexes that mediate memory are sequentially replaced in the brain and if this process is linked to protein lifetime. We address these issues by focusing on supercomplexes assembled by the abundant postsynaptic scaffolding protein PSD95, which plays a crucial role in memory. We used single-molecule detection, super-resolution microscopy and MINFLUX to probe the molecular composition of PSD95 supercomplexes in mice carrying genetically encoded HaloTags, eGFP, and mEoS2. We found a population of PSD95-containing supercomplexes comprised of two copies of PSD95, with a dominant 12.7 nm separation. Time-stamping of PSD95 subunits in vivo revealed that each PSD95 subunit was sequentially replaced over days and weeks. Comparison of brain regions showed subunit replacement was slowest in the cortex, where PSD95 protein lifetime is longest. Our findings reveal that protein supercomplexes within the postsynaptic density can be maintained by gradual replacement of individual subunits providing a mechanism for stable maintenance of their organization. Moreover, we extend Crick’s model by suggesting that synapses with slow subunit replacement of protein supercomplexes and long-protein lifetimes are specialized for long-term memory storage and that these synapses are highly enriched in superficial layers of the cortex where long-term memories are stored.
-
- Medicine
- Neuroscience
The advent of midazolam holds profound implications for modern clinical practice. The hypnotic and sedative effects of midazolam afford it broad clinical applicability. However, the specific mechanisms underlying the modulation of altered consciousness by midazolam remain elusive. Herein, using pharmacology, optogenetics, chemogenetics, fiber photometry, and gene knockdown, this in vivo research revealed the role of locus coeruleus (LC)-ventrolateral preoptic nucleus noradrenergic neural circuit in regulating midazolam-induced altered consciousness. This effect was mediated by α1 adrenergic receptors. Moreover, gamma-aminobutyric acid receptor type A (GABAA-R) represents a mechanistically crucial binding site in the LC for midazolam. These findings will provide novel insights into the neural circuit mechanisms underlying the recovery of consciousness after midazolam administration and will help guide the timing of clinical dosing and propose effective intervention targets for timely recovery from midazolam-induced loss of consciousness.